Apotex Backs Teva's En Banc Bid In Skinny Label Fight

By Tiffany Hu · October 21, 2021, 6:51 PM EDT

Generic-drug maker Apotex is asking the full Federal Circuit to let it weigh in on Teva's request for the appeals court to once again reconsider its decision to hold Teva liable...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief
Brief

Case Information

Case Title

GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

830 Patent Infringement (Fed. Qst.)

Date Filed

May 16, 2018

Recent Articles By Tiffany

June 13, 2023
Spinal Device Co. Gets $6M Bond Cut In Trade Secrets Suit
March 27, 2023
Wholesaler To Pay $33.4M In Abbott Labs Test Strips TM Row
February 16, 2023
TTAB Won't Let Diagnostic Co. Register 'NF-Light' TM
February 07, 2023
Instacart Co-Founder Hit With TRO In Trade Secrets Fight
January 20, 2023
Brand Battles: Uber Tries To Drive Out 'Uberhorny' Dating TM
January 04, 2023
TTAB Rejects Health Care Co.'s TM As Descriptive
March 21, 2022
Justices Skip $420M Secrets Suit, 'Candy Colors' Fight & More
March 09, 2022
Alvotech, AbbVie Deal Allows For Humira Biosimilar In 2023
February 25, 2022
Brand Battles: BetterUp Takes Aim At 'BetterHelp' Trademark
February 08, 2022
Sun Pharma, Lupin Agree To Drop Eye Pain Patent Dispute